Event content

Rapid and efficient development of drug candidates is increasingly important for pharmaceutical companies with accelerated timelines and funding constraints. However, many early drug candidates have poor oral absorption properties making it challenging to achieve target pharmacokinetic (PK) profiles. Witho...

Rapid and efficient development of drug candidates is increasingly important for pharmaceutical companies with accelerated timelines and funding constraints. However, many early drug candidates have poor oral absorption properties making it challenging to achieve target pharmacokinetic (PK) profiles. Witho...

AI an ever growing in pharma and is playing a prominent role in drug development. Listen to the latest developments in AI and what you need to know to utilize its potential in drug development. Join our focused session to get key takeaways from our expert: • Understanding what AI can bring to your orga...

In pharma, it is essential to identify the right partner to ensure a successful outcome. Time and time again, mistakes have been made in this process, causing clinical studies to fail and for the company to take a heavy hit. Want to avoid this? join our one-hour masterclass where we will devise a checklist...

New therapeutic treatments or prophylactic vaccines rely on more complicated drug formulations, often based on biologics. These drugs are highly sensitive and might require low temperature storage to keep them stable over shelf life. These extreme cold supply chain processes, something up to -80°C, provide...

Our healthcare industry is evolving. The move from IV to SC injection is being driven by lifecycle management, biosimilar adoption, and the hospital to home trend. Molecules are getting more complex, and patients drive the preference for self-administration resulting in the need for more complex combinatio...

In 2022, the final recommendations of the Product Quality Research Institute were published for Parenteral Drug Products. Apart from the wealth of information and considerations on design of extractable & leachable studies for parenteral drug products in general, it also contains valuable information on sp...

Transitioning drugs from IV to subcutaneous (SC) delivery brings new requirements and impacts program considerations for combination product development. In this session, we identify trade-offs that pharma weighs to de-risk combination product development programs involving large volume subcutaneous (LVSC...

Container closure integrity (CCI) testing is determined by evaluating whether a given container maintains its sterile barrier. It is a mandatory step in the design verification phase of a drug – device combination product development. Several methods exist with different advantages and limitations.
...

The acceleration of digital transformation across industries has been a prominent theme in the wake of COVID-19. In the pharmaceutical industry, the pandemic highlighted the need for agility and resiliency within the supply chain, fueling an increased urgency for the adoption of Pharma 4.0 technologies tha...

The complexity and risks found within the global pharma supply chain cannot be understated and key stakeholders from customers to regulators and investors are increasingly expecting the industry to both manage ESG risks and embed sustainability throughout the value chain. This can only be achieved through ...

BioPhorum has brought together biomanufacturers, supply partners, engineering partners, and regional innovation hubs to build a consensus strategy roadmap, encompassing considerations for all aspects of development from raw material to product, for the future of the industry. The roadmap will be presented ...

In this webinar, originally broadcast as part of the Pharmapack Europe show, Robert Schultheis, Founder & Chief Technology Officer, ZebraSci discusses: • Probabilistic vs deterministic CCI Testing • Presentation of the different deterministic CCI testing methods with applications and limitations ...

In this webinar, originally broadcast as part of the Pharmapack Europe show, Elina Iamsia and Klaus Heinisch from Edelmann Group, one of the leading manufacturers of paper-based packaging, discusses a range of perspectives on sustainability in packaging. They deep dive into a framework designed to illustra...

In this webinar, originally broadcast as part of the Pharmapack Europe show, speakers Michael Earl, Director Pharmaceutical Services, Sian Eden Business Development Manager, Olivia Houselander Business Development Manage, Denis Marteau General Manager, Pharmaceutical Services, Oli Gould Design Team Manager...

In this webinar, originally broadcast as part of the Pharmapack Europe show, Tom Oakley, Director of Drug Delivery Device Development, Springboard discusses 'Top Strategies for Environmental Sustainability with Examples'. Environmental sustainability is the defining challenge of our time. Whereas most glob...

In this webinar, originally broadcast as part of CPHI North America 2022, Frances Zipp, President and CEO, Lachmann Consultants Services discusses lessons learned and best practices for these relationships that can be applied to both accelerated approvals as well as “normal” drug supply during non-pandemic...

Focus on Medicines for All's work in process improvements for COVID therapeutics, including work done thus far on remdesivir and molnupiravir. The session will also describe how Medicines for All shares its results with the global market and how this has led to uptake of its processes on critical COVID dru...

Merger, acquisition, and consolidation activity in CRO/CDMO world has intensified to the point where many of my colleagues are beginning to wonder how big the global players can actually become. While many of the mid-sized players have disappeared, a huge number of small pharma service organizations are th...

Discuss strategies and methodologies to develop scalable, robust, and cost-effective manufacturing processes for allogeneic cell therapies Showcase how induced pluripotent stem cells (iPSC) are being used as renewable sources of allogeneic cancer therapies Demonstrate the criticality of GMP manufacturing...